AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 302 min read$IONS

Schneider Eugene sold $2.1M of IONS

Schneider Eugene (EVP, Chf Clinical Develop Ofcr) sold 26,000 shares of IONIS PHARMACEUTICALS INC (IONS) at $81.05 ($2.11M total) on 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schneider Eugene
Published Jun 30, 2026, 9:48 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$IONS
Neutral
medium confidence
Mentioned
$IONS
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IONSNeutralLow
01

Why it matters

The only new information is the transaction size, price, and post-sale holdings; it may slightly influence sentiment but does not change the company’s outlook based on the text provided.

02

Market read

Traders may monitor for follow-on insider activity, but this specific filing is unlikely to drive a major repricing without accompanying fundamental news.

03

What to watch

The filing doesn’t disclose reasons for the sale or any concurrent operational/clinical updates; traders should avoid extrapolating fundamentals from a single transaction.

Relevance 5/10Novelty 5/10Timing: filed after-hours on June 30; reflects sale executed June 26

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by an Ionis EVP under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$IONSNeutralMedium confidence
Context

Ionis Pharmaceuticals disclosed an EVP’s open-market sale of 26,000 shares at $81.0460 on a 10b5-1 plan, filed June 30.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional catalyst from the filing alone.

Evidence & confidence

The filing is a routine Form 4 with a stated 10b5-1 pre-arranged plan; it provides transaction details but no new company fundamentals.

Market effects

Sector

Minimal; this is company-specific insider activity with no disclosed sector-wide regulatory/clinical catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a 10b5-1 plan, it may be mechanically scheduled and not a bearish signal.

Key entities

  • issuer
    IONIS PHARMACEUTICALS INC

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Schneider Eugene

    EVP, Chief Clinical Development Officer; sold 26,000 shares under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 8
$IONSMedAI 8/10

Ionis (IONS) Q2 2026 Earnings Call Transcript

Ionis Pharmaceuticals (IONS) reported Q2 2026 total revenue of $268 million, up 56% excluding a one-time Sapablursen payment. Commercial revenue was $119 million, driven by DAWNZERA sales of $26 million (+63% QoQ). 2026 guidance: $875 million to $900 million revenue and non-GAAP operating loss of $425 million to $475 million. Cash was $2.1 billion.

aol.com7 min
JUL 30
$IONSMed

Ionis Pharmaceuticals: Q2 Earnings Snapshot

Ionis Pharmaceuticals (IONS) reported a Q2 loss of $115 million, or 69 cents per share. Adjusted for stock option expense, the loss was 43 cents per share. Revenue was $268 million, above Street expectations of $190.7 million, according to Zacks.

aol.com2 min
JUL 29
$IONSMedAI 8/10

IONIS PHARMACEUTICALS INC (IONS): Results of Operations and Financial Condition

IONIS PHARMACEUTICALS INC (IONS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20078953_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ionis reports second quarter 2026 financial results and highlights progress on key programs - TRYNGOLZA ® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large p

SEC EDGAR 8-K6 min
JUL 25
$IONSMed

Ionis Pharmaceuticals (IONS) Trial Setback Sparks Scrutiny, Is The 38% Undervaluation Case Still Credible?

Ionis Pharmaceuticals (IONS) said its late-stage CARDIO TTRansform trial of eplontersen with AstraZeneca did not meet the primary efficacy endpoint, prompting a sharp share drop and a shareholder investigation. The stock was down 26.1% over 30 days and 29.0% YTD. The article cites a $92 fair value versus $56.55 last close and discusses valuation metrics including P/S 8.8x.

simplywall.st5 min
JUL 23
$IONSMed

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS

Ionis Pharmaceuticals (NASDAQ: IONS) shares fell about 23% on July 9, 2026 after it and AstraZeneca reported the Phase 3 CARDIO-TTRansform trial of eplontersen for ATTR-CM did not meet the primary efficacy endpoint. The company said adding eplontersen was not statistically beneficial in a contemporary standard-of-care population. Hagens Berman opened an investor-fraud investigation into trial transparency.

prnewswire.com3 min